RBC Capital Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $74
RBC Capital analyst Brian Abrahams maintains $Gilead Sciences(GILD.US)$ with a hold rating, and maintains the target price at $74.According to TipRanks data, the analyst has a success rate of 49.4% an
EU to Require Additional Cancer Risk Labeling on CAR T Therapies
Gilead Stock Gains. It's Trying to Get Into the Obesity Drug Game.
A success would be a gamechanger for the biotech company known for its HIV treatments.
What 8 Analyst Ratings Have To Say About Gilead Sciences
In the last three months, 8 analysts have published ratings on Gilead Sciences (NASDAQ:GILD), offering a diverse range of perspectives from bullish to bearish.The table below provides a snapshot of th
Gilead Spikes as Jefferies Highlights Weight Loss Prospects
Express News | RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $74 Price Target
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $80
Jefferies analyst Michael Yee maintains $Gilead Sciences(GILD.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 44.0% and a to
Gilead Sciences Inc's Dividend Analysis
Gilead Sciences' Kite Unit Reports Positive Data From New Analyses of Yescarta
Gilead Sciences' (GILD) Kite unit said Friday that results from three new analyses of Yescarta, or axicabtagene ciloleucel, in relapsed/refractory large B-cell lymphoma demonstrated the potential bene
Express News | Gilead's Kite Revealed New Data On Yescarta And Tecartus Outpatient Administration At EHA 2024
Express News | Gilead- Analysis Shows Yescarta in Second-Line Treatment of Relapsed/Refractory Large B-Cell Lymphoma Help Reduce Time From Leukapheresis to Infusion
Express News | Gilead - Preliminary Results Supporting Safety and Feasibility of Outpatient Administration of Yescarta and Tecartus to Be Presented
Express News | New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Gilead Sciences To Go Ex-Dividend On June 14th, 2024 With 0.77 USD Dividend Per Share
June 12th (Eastern Time) - $Gilead Sciences(GILD.US)$ is trading ex-dividend on June 14th, 2024.Shareholders of record on June 14th, 2024 will receive 0.77 USD dividend per share on June 27th, 2024. T
Express News | Gilead Exec Says Co Will Will Continue to Look at Smaller Deals Worth "Mid-Single-Digit Billions" on Average Every Few Years - Goldman Sachs Conf
How Luciana Preger Is Helping Advance Gilead's Work in Oncology
NORTHAMPTON, MA / ACCESSWIRE / June 12, 2024 / Gilead SciencesLuciana Preger credits being exposed to her father's work at a young age with helping inform her own career in medicine. Luciana is a phys
Arcus Biosciences In Collaboration With Gilead Sciences, Completes Patient Enrollment In Phase 3 Trial Evaluating A Domvanalimab-Containing Regimen In First-Line Metastatic Upper GI Cancers
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient populationArcus Biosciences, Inc. (NYS
No Data